{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:26:21Z","timestamp":1791591981034,"version":"4.3.4"},"reference-count":104,"publisher":"Elsevier","isbn-type":[{"value":"9780443241147","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.pmbts.2024.04.002","type":"book-chapter","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T17:10:01Z","timestamp":1715620201000},"page":"59-78","source":"Crossref","is-referenced-by-count":4,"title":["Drug repurposing for fungal infections"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.pmbts.2024.04.002_bib1","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s10096-017-2909-8","article-title":"Calling upon all public health mycologists: to accompany the country burden papers from 14 countries","volume":"36","author":"Denning","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib2","doi-asserted-by":"crossref","first-page":"165rv113","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden killers: human fungal infections","volume":"4","author":"Brown","year":"2012","journal-title":"Sci Transl Med."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.tim.2014.01.001","article-title":"A neglected epidemic: fungal infections in HIV\/AIDS","volume":"22","author":"Armstrong-James","year":"2014","journal-title":"Trends Microbiol."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib4","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Livio","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/bs.pmbts.2024.04.002_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/nyas.13739","article-title":"New pathogens, new tricks: emerging, drug-resistant fungal pathogens and future prospects for antifungal therapeutics","volume":"1435","author":"Geddes-McAlister","year":"2019","journal-title":"Ann N Y Acad Sci."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib6","first-page":"1","article-title":"A rare fungal infiltration of lungs in a healthy young girl","volume":"2011","author":"Gupta","year":"2011","journal-title":"Case Rep Pulmonol."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib7","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2217\/1745509X.2.6.1013","article-title":"Oral infections in older adults","volume":"2","author":"Meurman","year":"2006","journal-title":"Aging Health"},{"key":"10.1016\/bs.pmbts.2024.04.002_bib8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/bjh.12896","article-title":"Current status of antifungal resistance and its impact on clinical practice","volume":"166","author":"Alcazar-Fuoli","year":"2014","journal-title":"Br J Haematol."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ddtec.2014.02.005","article-title":"Overcoming antifungal resistance","volume":"11","author":"Srinivasan","year":"2014","journal-title":"Drug Discov Today Technol."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd.2017.46","article-title":"The antifungal pipeline: a reality check","volume":"16","author":"Perfect","year":"2017","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02213-20","article-title":"Effects of agricultural fungicide use on Aspergillus fumigatus: abundance, antifungal susceptibility, and population structure","volume":"11","author":"Barber","year":"2020","journal-title":"mBio"},{"key":"10.1016\/bs.pmbts.2024.04.002_bib12","doi-asserted-by":"crossref","first-page":"12040","DOI":"10.1073\/pnas.1807698115","article-title":"Evolution of drug resistance in an antifungal-naive chronic Candida lusitaniae infection","volume":"115","author":"Demers","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/bs.pmbts.2024.04.002_bib13","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/nrd4675","article-title":"Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?","volume":"4","author":"Brown","year":"2015","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib14","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1128\/AAC.03137-14","article-title":"In vitro analysis of finasteride activity against Candida albicans urinary biofilm formation and filamentation","volume":"58","author":"Chavez-Dozal","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cellsig.2017.04.001","article-title":"Niclosamide: beyond an antihelminthic drug","volume":"41","author":"Chen","year":"2018","journal-title":"Cell Signal"},{"key":"10.1016\/bs.pmbts.2024.04.002_bib16","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.3390\/ijerph7052337","article-title":"Medical applications and toxicities of gallium compounds","volume":"7","author":"Chitambar","year":"2010","journal-title":"Int J Env Res Public Health"},{"key":"10.1016\/bs.pmbts.2024.04.002_bib17","doi-asserted-by":"crossref","first-page":"15653","DOI":"10.1038\/s41598-017-15969-3","article-title":"The immunomodulatory drug glatiramer acetate is also an effective antimicrobial agent that kills gram-negative bacteria","volume":"7","author":"Christiansen","year":"2017","journal-title":"Sci Rep."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib18","doi-asserted-by":"crossref","first-page":"8369","DOI":"10.1038\/ncomms9369","article-title":"Tamoxifen augments the innate immune function of neutrophils through modulation of intracellular ceramide","volume":"6","author":"Corriden","year":"2015","journal-title":"Nat Commun."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib19","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1021\/acs.molpharmaceut.5b00098","article-title":"Towards repositioning niclosamide for anti-virulence therapy of Pseudomonas aeruginosa lung infections: development of inhalable formulations through nanosuspension technology","volume":"12","author":"Costabile","year":"2015","journal-title":"Mol Pharm."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib20","doi-asserted-by":"crossref","first-page":"a019752","DOI":"10.1101\/cshperspect.a019752","article-title":"Mechanisms of antifungal drug resistance","volume":"5","author":"Cowen","year":"2015","journal-title":"Cold Spring Harb Perspect Med."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib21","article-title":"Identification of FDA-approved drugs as antivirulence agents targeting the pqs quorum sensing system of Pseudomonas aeruginosa","volume":"62","author":"D\u2019Angelo","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib22","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1128\/AAC.00778-12","article-title":"In vitro and in vivo biological activities of iron chelators and gallium nitrate against Acinetobacter baumannii","volume":"56","author":"De L\u00e9s\u00e9leuc","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib23","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/jac\/dkt449","article-title":"Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms","volume":"69","author":"Delattin","year":"2014","journal-title":"J Antimicrob Chemother."},{"issue":"8","key":"10.1016\/bs.pmbts.2024.04.002_bib24","first-page":"4984","article-title":"Unlocking therapeutic potential: integration of drug repurposing and immunotherapy for various disease targeting","volume":"15","author":"Pawar","year":"2023","journal-title":"Am J Transl Res."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00765-13","article-title":"Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo","volume":"5","author":"Butts","year":"2014","journal-title":"mBio"},{"key":"10.1016\/bs.pmbts.2024.04.002_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.12.4.501","article-title":"Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance","volume":"12","author":"Ghannoum","year":"1999","journal-title":"Clin Microbiol Rev."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.fgb.2019.103254","article-title":"Facilitators of adaptation and antifungal resistance mechanisms in clinically relevant fungi","volume":"132","author":"Hokken","year":"2019","journal-title":"Fungal Genet Biol."},{"issue":"13","key":"10.1016\/bs.pmbts.2024.04.002_bib28","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1007\/s00253-021-11407-7","article-title":"Drug repurposing strategies in the development of potential antifungal agents","volume":"105","author":"Zhang","year":"2021","journal-title":"Appl Microbiol Biotechnol."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/nchembio.1496","article-title":"Amphotericin forms an extramembranous and fungicidal sterol sponge","author":"Anderson","year":"2014","journal-title":"Nat Chem."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.04.002_bib30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1086\/376634","article-title":"Amphotericin B: time for a new \u201cgold standard\u201d","volume":"37","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Clin Infect Dis."},{"issue":"4","key":"10.1016\/bs.pmbts.2024.04.002_bib31","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis."},{"issue":"6","key":"10.1016\/bs.pmbts.2024.04.002_bib32","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/jac\/dkl392","article-title":"Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species","volume":"58","author":"O\u2019Shaughnessy","year":"2006","journal-title":"J Antimicrob Chemother."},{"issue":"11","key":"10.1016\/bs.pmbts.2024.04.002_bib33","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2165\/00003495-200565110-00002","article-title":"Antifungal combination therapy: clinical potential","volume":"65","author":"Baddley","year":"2005","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/bs.pmbts.2024.04.002_bib34","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/TP.0000000000002353","article-title":"How we approach combination antifungal therapy for invasive aspergillosis and mucormycosis in transplant recipients","volume":"102","author":"Haidar","year":"2018","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.04.002_bib35","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/374553","article-title":"Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics","volume":"36","author":"Roden","year":"2003","journal-title":"Clin Infect Dis."},{"issue":"4","key":"10.1016\/bs.pmbts.2024.04.002_bib36","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00204-016-1916-3","article-title":"New developments and directions in the clinical application of the echinocandins","volume":"91","author":"Chang","year":"2017","journal-title":"Arch Toxicol."},{"issue":"8","key":"10.1016\/bs.pmbts.2024.04.002_bib37","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1007\/s00253-013-4761-9","article-title":"Echinocandins: production and applications","volume":"97","author":"Emri","year":"2013","journal-title":"Appl Microbiol Biotechnol."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.04.002_bib38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1198-743X.2004.00823.x","article-title":"Caspofungin--a new therapeutic option for oropharyngeal Candidiasis","volume":"10","author":"Garbino","year":"2004","journal-title":"Clin Microbiol Infect."},{"issue":"11","key":"10.1016\/bs.pmbts.2024.04.002_bib39","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1128\/AAC.46.11.3634-3636.2002","article-title":"In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies","volume":"46","author":"Ramage","year":"2002","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejmech.2017.04.044","article-title":"An overview of azoles targeting sterol 14\u03b1-demethylase for antileishmanial therapy","volume":"135","author":"Emami","year":"2017","journal-title":"Eur J Med Chem."},{"issue":"1709","key":"10.1016\/bs.pmbts.2024.04.002_bib41","doi-asserted-by":"crossref","first-page":"20150460","DOI":"10.1098\/rstb.2015.0460","article-title":"Clinical implications of globally emerging azole resistance in Aspergillus fumigatus","volume":"371","author":"Meis","year":"2016","journal-title":"Philos Trans R Soc Lond Ser B Biol Sci."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib42","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1146\/annurev-micro-030117-020345","article-title":"Molecular evolution of antifungal drug resistance","volume":"71","author":"Robbins","year":"2017","journal-title":"Annu Rev Microbiol."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib43","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/IDR.S124918","article-title":"Antifungal resistance: current trends and future strategies to combat","volume":"10","author":"Wiederhold","year":"2017","journal-title":"Infect Drug Resist."},{"issue":"30","key":"10.1016\/bs.pmbts.2024.04.002_bib44","article-title":"Emerging aspergillosis by azole-resistant Aspergillus fumigatus at an intensive care unit in the Netherlands, 2010 to 2013","volume":"21","author":"Paassen","year":"2016","journal-title":"Euro Surveill."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.04.002_bib45","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ijantimicag.2017.09.002","article-title":"The antifungal arsenal: alternative drugs and future targets","volume":"51","author":"Wiederhold","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"suppl 1","key":"10.1016\/bs.pmbts.2024.04.002_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1469-0691.2010.03448.x","article-title":"Anidulafungin for the treatment of invasive Candidiasis","volume":"17","author":"Mayr","year":"2011","journal-title":"Clin Microbiol Infect."},{"issue":"11","key":"10.1016\/bs.pmbts.2024.04.002_bib47","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1128\/JCM.43.11.5425-5427.2005","article-title":"In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole","volume":"43","author":"Pfaller","year":"2005","journal-title":"J Clin Microbiol."},{"issue":"suppl 1","key":"10.1016\/bs.pmbts.2024.04.002_bib48","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/11315560-000000000-00000","article-title":"Anidulafungin, a new echinocandin: in vitro activity","volume":"69","author":"Morace","year":"2009","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.04.002_bib49","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1128\/JCM.00942-09","article-title":"In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods","volume":"47","author":"Diekema","year":"2009","journal-title":"J Clin Microbiol."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib50","doi-asserted-by":"crossref","unstructured":"Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol. 2008;46(1):150\u20136. https:\/\/doi.org\/10.1128\/JCM.01901-07. Epub 2007 Nov 21. Erratum in: J Clin Microbiol. 2008 Sep;46(9):3184\u20135.","DOI":"10.1128\/JCM.01107-08"},{"key":"10.1016\/bs.pmbts.2024.04.002_bib51","first-page":"475","article-title":"Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B","volume":"46","author":"Cuenca-Estrella","year":"2000"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.04.002_bib52","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Sobel JD; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis."},{"issue":"24","key":"10.1016\/bs.pmbts.2024.04.002_bib53","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive Candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.04.002_bib54","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1592\/phco.27.3.369","article-title":"The echinocandins","volume":"27","author":"Cappelletty","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.04.002_bib55","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1128\/JCM.44.3.760-763.2006","article-title":"In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance","volume":"44","author":"Pfaller","year":"2006","journal-title":"J Clin Microbiol."},{"issue":"9390","key":"10.1016\/bs.pmbts.2024.04.002_bib56","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"362","author":"Denning","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.04.002_bib57","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/tcrm.2007.3.1.71","article-title":"Comparison of echinocandin antifungals","volume":"3","author":"Eschenauer","year":"2007","journal-title":"Ther Clin Risk Manag."},{"issue":"8","key":"10.1016\/bs.pmbts.2024.04.002_bib58","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1128\/AAC.49.8.3264-3273.2005","article-title":"Specific substitutions in the echinocandin target Fksp1 account for reduced susceptibility of rare laboratory and clinical Candida species isolates","volume":"49","author":"Park","year":"2005","journal-title":"Antimicrob Agents Chemother."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.04.002_bib59","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.cll.2004.05.003","article-title":"Emerging fungal resistance","volume":"24","author":"Baddley","year":"2004","journal-title":"Clin Lab Med."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib60","first-page":"27","article-title":"Micafungin: an evidence-based review of its place in therapy","volume":"9","author":"De La Torre","year":"2014","journal-title":"Core Evid."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib61","doi-asserted-by":"crossref","first-page":"e0006479","DOI":"10.1371\/journal.pntd.0006479","article-title":"Searching for a change: the need for increased support for public health and research on fungal diseases","volume":"6","author":"Rodrigues","year":"2018","journal-title":"PLoS Negl Trop Dis."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib62","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/713687","article-title":"Antifungal resistance and new strategies to control fungal infections","volume":"2012","author":"Vandeputte","year":"2012","journal-title":"Int J Microbiol."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib63","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/cid\/ciw691","article-title":"Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses","volume":"64","author":"Lockhart","year":"2016","journal-title":"Clin Infect Dis."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib64","doi-asserted-by":"crossref","first-page":"1065962","DOI":"10.3389\/fcimb.2022.1065962","article-title":"Repurposing non-antifungal drugs auranofin and pentamidine in combination as fungistatic antifungal agents against C. albicans","volume":"12","author":"Lin","year":"2022","journal-title":"Front Cell Infect Microbiol."},{"issue":"6","key":"10.1016\/bs.pmbts.2024.04.002_bib65","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11886-021-01484-5","article-title":"Drug repurposing: claiming the full benefit from drug development","volume":"23","author":"Kort","year":"2021","journal-title":"Curr Cardiol Rep."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib66","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fmicb.2019.00041","article-title":"Drug repurposing for the treatment of bacterial and fungal infections","volume":"10","author":"Mir\u00f3","year":"2019","journal-title":"Front Microbiol."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib67","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ijantimicag.2016.06.023","article-title":"Molecular mechanisms of polymyxin resistance: knowns and unknowns","volume":"48","author":"Baron","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/bs.pmbts.2024.04.002_bib68","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13756-019-0521-7","article-title":"In vitro polymyxin activity against clinical multidrug-resistant fungi","volume":"8","author":"Yousfi","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/bs.pmbts.2024.04.002_bib69","doi-asserted-by":"crossref","DOI":"10.1021\/acsinfecdis.0c00721","article-title":"Combining colistin and fluconazole synergistically increases fungal membrane permeability and antifungal cidality","volume":"7","author":"Bibi","year":"2021","journal-title":"ACS Infect Dis."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib70","first-page":"218","article-title":"Mechanism of action of ribavirin in the treatment of chronic hepatitis C","volume":"3","author":"Te","year":"2007","journal-title":"Gastroenterol Hepatol."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171145","article-title":"Identification of small molecules that disrupt vacuolar function in the pathogen Candida albicans","volume":"12","author":"Tournu","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.04.002_bib72","doi-asserted-by":"crossref","first-page":"e00263-19","DOI":"10.1128\/AAC.00263-19","article-title":"Repurposing of ribavirin as an adjunct therapy against invasive Candida strains in an in vitro study","volume":"63","author":"Yousfi","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib73","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/mmy\/myy027","article-title":"Repurposing the anthelminthic salicylanilide oxyclozanide against susceptible and clinical resistant Candida albicans strains","volume":"57","author":"Pic","year":"2019","journal-title":"Med Mycol."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib74","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijantimicag.2007.05.015","article-title":"Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century","volume":"30","author":"Rolain","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/bs.pmbts.2024.04.002_bib75","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40261-018-0656-y","article-title":"Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review","volume":"38","author":"Plantone","year":"2018","journal-title":"Clin Drug Investig."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib76","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S1369-5274(00)00102-8","article-title":"Chloroquine and the fungal phagosome","volume":"3","author":"Weber","year":"2000","journal-title":"Curr Opin Microbiol."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003083","article-title":"Discovering thiamine transporters as targets of chloroquine using a novel functional genomics strategy","volume":"8","author":"Huang","year":"2012","journal-title":"PLoS Genet."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib78","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2323\/jgam.59.167","article-title":"An in vitro repositioning study reveals antifungal potential of chloroquine to inhibit growth and morphogenesis in Candida albicans","volume":"59","author":"Shinde","year":"2013","journal-title":"J Gen Appl Microbiol."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib79","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1128\/AAC.02810-15","article-title":"Repurposing of aspirin and ibuprofen as candidate anti-Cryptococcus drugs","volume":"60","author":"Ogundeji","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib80","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1099\/0022-1317-49-9-831","article-title":"Antifungal activity of ibuprofen alone and in combination with fluconazole against Candida species","volume":"49","author":"Pina-Vaz","year":"2000","journal-title":"J Med Microbiol."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib81","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1128\/AAC.39.12.2610","article-title":"Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro","volume":"39","author":"Scott","year":"1995","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib82","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1128\/AAC.00377-16","article-title":"Screening a commercial library of pharmacologically active small molecules against Staphylococcus aureus biofilms","volume":"60","author":"Torres","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib83","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01084-18","article-title":"Screening a repurposing library for inhibitors of multidrug-resistant Candida auris identifies ebselen as a repositionable candidate for antifungal drug development","volume":"62","author":"Wall","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib84","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/AAC.01087-13","article-title":"Antifungal application of nonantifungal drugs","volume":"58","author":"Stylianou","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib85","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01921-19","article-title":"Identification of off-patent drugs that show synergism with amphotericin B or that present antifungal action against Cryptococcus neoformans and Candida spp","volume":"64","author":"Rossi","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib86","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/jam.14443","article-title":"Antibiofilm efficacy of the gold compound auranofin on dual species biofilms of Staphylococcus aureus and Candida spp","volume":"128","author":"She","year":"2020","journal-title":"J Appl Microbiol."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib87","article-title":"Drug repurposing of haloperidol: discovery of new benzocyclane derivatives as potent antifungal agents against Cryptococcosis and Candidiasis","volume":"6","author":"Ji","year":"2019","journal-title":"ACS Infect Dis."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib88","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejmech.2017.07.030","article-title":"Repurposing antipsychotic drugs into antifungal agents: synergistic combinations of azoles and bromperidol derivatives in the treatment of various fungal infections","volume":"139","author":"Holbrook","year":"2017","journal-title":"Eur J Med Chem."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib89","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1439-0507.2007.01371.x","article-title":"Activity and post antifungal effect of chlorpromazine and trifluopherazine against Aspergillus, Scedosporium and zygomycetes","volume":"50","author":"Vitale","year":"2007","journal-title":"Mycoses"},{"key":"10.1016\/bs.pmbts.2024.04.002_bib90","doi-asserted-by":"crossref","DOI":"10.1111\/j.1439-0507.2010.02010.x","article-title":"In vitro antifungal activity of phenothiazines and their combination with amphotericin B against different Candida species","volume":"54","author":"Galg\u00f3czy","year":"2011","journal-title":"Mycoses"},{"key":"10.1016\/bs.pmbts.2024.04.002_bib91","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/mmy\/myv064","article-title":"In vitro antifungal activity of antipsychotic drugs and their combinations with conventional antifungals against Scedosporium and Pseudallescheria isolates","volume":"53","author":"Homa","year":"2015","journal-title":"Med Mycol."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib92","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02272-18","article-title":"Repurposing estrogen receptor antagonists for the treatment of infectious disease","volume":"9","author":"Montoya","year":"2018","journal-title":"mBio"},{"key":"10.1016\/bs.pmbts.2024.04.002_bib93","doi-asserted-by":"crossref","first-page":"e765","DOI":"10.1128\/mBio.00765-13","article-title":"Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo","volume":"5","author":"Butts","year":"2014","journal-title":"mBio"},{"key":"10.1016\/bs.pmbts.2024.04.002_bib94","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1128\/AAC.01564-08","article-title":"Antifungal activity of tamoxifen: in vitro and in vivo activities and mechanistic characterization","volume":"53","author":"Dolan","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib95","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125927","article-title":"Structure-activity relationships for the antifungal activity of selective estrogen receptor antagonists related to tamoxifen","volume":"10","author":"Butts","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/bs.pmbts.2024.04.002_bib96","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00079-20","article-title":"NADPH-cytochrome P450 reductase ccr1 is a target of tamoxifen and participates in its antifungal activity via regulating cell wall integrity in fission yeast","volume":"64","author":"Liu","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib97","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/14787210.2020.1752665","article-title":"Repurposed anti-cancer drugs: the future for anti-infective therapy?","volume":"18","author":"Quezada","year":"2020","journal-title":"Expert Rev Anti Infect Ther."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.04.002_bib98","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/myc.13203","article-title":"Alternative treatment of fungal infections: synergy with non-antifungal agents","volume":"64","author":"Rossato","year":"2020","journal-title":"Mycoses"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.04.002_bib99","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/mmy\/myaa071","article-title":"Antifungal efficacy of atorvastatin-containing emulgel in the treatment of oral and vulvovaginal candidiasis","volume":"59","author":"De Oliveira Neto","year":"2020","journal-title":"Med Mycol."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1574-6968.2006.00370.x","article-title":"Growth inhibition of Candida species and Aspergillus fumigatus by statins","volume":"262","author":"Macreadie","year":"2006","journal-title":"FEMS Microbiol Lett."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib101","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ijantimicag.2017.04.005","article-title":"Atorvastatin as a promising anticryptococcal agent","volume":"49","author":"De Queiroz Ribeiro","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/bs.pmbts.2024.04.002_bib102","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.mycmed.2019.07.004","article-title":"Insights on the anticandidal activity of non-antifungal drugs","volume":"29","author":"Moraes","year":"2019","journal-title":"J Mycol Med."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib103","doi-asserted-by":"crossref","first-page":"7525","DOI":"10.1038\/s41598-020-64571-7","article-title":"Repurposing approach identifies pitavastatin as a potent azole chemosensitizing agent effective against azole-resistant Candida species","volume":"10","author":"Eldesouky","year":"2020","journal-title":"Sci Rep."},{"key":"10.1016\/bs.pmbts.2024.04.002_bib104","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cmi.2016.03.026","article-title":"The refusal of the Society to accept antibiotic toxicity: missing opportunities for therapy of severe infections","volume":"22","author":"Rolain","year":"2016","journal-title":"Clin Microbiol Infect."}],"container-title":["Progress in Molecular Biology and Translational Science","Clinical Application of Repurposed Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117324000942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117324000942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:14:04Z","timestamp":1753355644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117324000942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443241147"],"references-count":104,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2024.04.002","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}